Please assess the completion status of the following clinical trial:

Trial Title: A Study of RO7123520 to Evaluate the Safety and Efficacy in Participants With Moderately To Severely Active Rheumatoid Arthritis (RA) Who Are Inadequately Responding to Anti-Tumor Necrosis Factor (TNF)-Alpha Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of adult-onset RA as defined by the ACR 2010 criteria, for at least 6 months before screening~* Moderately to severely active RA as defined by at least 4/28 tender joints and at least 4/28 swollen joints, and a DAS28 greater than or equal to (≥) 3.2~* For Part 2 only: Active synovitis and/or osteitis as determined by contrast-enhanced magnetic resonance imaging~* Participants must be taking stable dose of anti-TNF-alpha therapies~* Participants on stable oral glucocorticoids within 6 weeks of planned randomization~* Participants taking non-steroidal anti-inflammatory drugs (NSAIDs) intermittently (up to 2-3 times weekly) for short-term relief of pain and participants on regular NSAID use (on stable dose for ≥ 4 weeks)~Exclusion Criteria:~* Parenteral glucocorticoids administration (intramuscular, IV) of ≥50 mg within 6 weeks or less than or equal to (≤) 50 milligrams (mg) within 4 weeks prior to planned randomization, or scheduled parenteral administrations during the study~* Joint(s) injected with intra-articular glucocorticoids or hyaluronic acid within 6 weeks prior to planned randomization~* Active inflammatory diseases of the joints not related to RA~* Systemic autoimmune disease other than RA~* Juvenile idiopathic arthritis or juvenile RA and/or RA developed before the age of 16~* Active fibromyalgia that makes appropriate assessment of RA disease activity challenging in the opinion of the Investigator~* RA participants functional status class IV according to the ACR 1991 criteria~* Participants with severe chronic or recurrent viral, bacterial, parasitic, or fungal infections~* History of active hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV) infection~* Any identified confirmed congenital or acquired immunodeficiency~* Abnormal laboratory values and liver function test~* Myocardial infarction within less than 6 months prior to participation in the study~* Severe central or peripheral nervous system diseases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part 1: Placebo (Type: PLACEBO_COMPARATOR): Participants will receive placebo (matched to RO7123520) on Days 1, 14, 28, and 56 with pre-trial anti-TNF-alpha and methotrexate.
- Part 1: RO7123520 (Type: EXPERIMENTAL): Participants will receive RO7123520 on Days 1, 14, 28, and 56 with pre-trial anti-TNF-alpha and methotrexate.
- Part 2: Placebo (Type: PLACEBO_COMPARATOR): Participants will receive placebo (matched to RO7123520) on Days 1, 14, 28, and 56 with pre-trial anti-TNF-alpha and methotrexate.
- Part 2: RO7123520 (Type: EXPERIMENTAL): Participants will receive RO7123520 on Days 1, 14, 28, and 56 with pre-trial anti-TNF-alpha and methotrexate.
- Part 3: Placebo (Type: PLACEBO_COMPARATOR): Participants will receive placebo (matched to RO7123520) on Days 1, 14, 28, and 56 with pre-trial anti-TNF-alpha and methotrexate.~NOTE: Part 3 was not conducted.
- Part 3: RO7123520 (Type: EXPERIMENTAL): Participants will receive RO7123520 on Days 1, 14, 28, and 56 with pre-trial anti-TNF-alpha and methotrexate.~NOTE: Part 3 was not conducted.

Based on this trial design, predict the completion outcome and termination type (if applicable).